Xiu Juan Zhang1, Qing Yun Li, Yan Wang, Hua Jun Xu, Ying Ni Lin. 1. Department of Respiratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, 200025, China.
Abstract
PURPOSE: Although there is a high co-occurrence of insomnia and obstructive sleep apnea (OSA), the administration of sedative hypnotics in patients with OSA is still inconsistent. The aim is to study the effect of non-benzodiazepine hypnotics (non-BZDs) on sleep quality and severity in patients with OSA. METHODS: We conducted a systemic search for controlled clinical trials in multiple databases and pooled analysis of the impact of non-BZDs on objective sleep quality and the severity of OSA, including the apnea-hypopnea index (AHI) and mean and nadir arterial oxygen saturation (SaO2) in patients with OSA. Sensitivity analysis was carried out to explore the robustness of results. RESULTS: Eight relevant placebo-controlled clinical trials involving 448 patients were included. Objective sleep quality, including sleep latency, sleep efficiency, and wake time after sleep onset, was significantly improved in patients taking non-BZDs compared with those taking placebo (p<0.01). The weighted estimate indicated that the administration of non-BZDs prior to bedtime had no significant effect on AHI or SaO2 in OSA patients (p>0.05). CONCLUSIONS: The administration of non-BZDs at the commonly recommended dose has been shown to improve objective sleep quality in OSA patients without worsening sleep apnea. It suggests that OSA patients with a complaint of insomnia symptoms may benefit from taking non-BZDs.
PURPOSE: Although there is a high co-occurrence of insomnia and obstructive sleep apnea (OSA), the administration of sedative hypnotics in patients with OSA is still inconsistent. The aim is to study the effect of non-benzodiazepine hypnotics (non-BZDs) on sleep quality and severity in patients with OSA. METHODS: We conducted a systemic search for controlled clinical trials in multiple databases and pooled analysis of the impact of non-BZDs on objective sleep quality and the severity of OSA, including the apnea-hypopnea index (AHI) and mean and nadir arterial oxygen saturation (SaO2) in patients with OSA. Sensitivity analysis was carried out to explore the robustness of results. RESULTS: Eight relevant placebo-controlled clinical trials involving 448 patients were included. Objective sleep quality, including sleep latency, sleep efficiency, and wake time after sleep onset, was significantly improved in patients taking non-BZDs compared with those taking placebo (p<0.01). The weighted estimate indicated that the administration of non-BZDs prior to bedtime had no significant effect on AHI or SaO2 in OSA patients (p>0.05). CONCLUSIONS: The administration of non-BZDs at the commonly recommended dose has been shown to improve objective sleep quality in OSA patients without worsening sleep apnea. It suggests that OSA patients with a complaint of insomnia symptoms may benefit from taking non-BZDs.
Authors: Michael A Coyle; Wallace B Mendelson; P Alexander Derchak; Steven P James; Michael G Wilson Journal: J Clin Sleep Med Date: 2005-01-15 Impact factor: 4.062
Authors: Erla Björnsdóttir; Christer Janson; Thorarinn Gíslason; Jón F Sigurdsson; Allan I Pack; Philip Gehrman; Bryndís Benediktsdóttir Journal: J Sleep Res Date: 2011-10-12 Impact factor: 3.981
Authors: Rajeev Ratnavadivel; Nuy Chau; Daniel Stadler; Aeneas Yeo; R Doug McEvoy; Peter G Catcheside Journal: J Clin Sleep Med Date: 2009-12-15 Impact factor: 4.062
Authors: Peter J Colvonen; Laura D Straus; Carl Stepnowsky; Michael J McCarthy; Lizabeth A Goldstein; Sonya B Norman Journal: Curr Psychiatry Rep Date: 2018-06-21 Impact factor: 5.285
Authors: Alexander Sweetman; Leon Lack; R Doug McEvoy; Nick A Antic; Simon Smith; Ching Li Chai-Coetzer; James Douglas; Amanda O'Grady; Nicola Dunn; Jan Robinson; Denzil Paul; Danny Eckert; Peter G Catcheside Journal: ERJ Open Res Date: 2020-05-17